iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
NuSynth Technologies has raised ₹36.5 crore in a seed round co-led by Avaana Capital and Shastra VC, according to reports published on 13 October 2026. The startup is developing an R&D-led platform for process innovation in complex chemistry, with pharmaceuticals and electronics chemicals as its initial target sectors.
What NuSynth raised and who backed the round
The seed round totals ₹36.5 crore. The Economic Times/ETtech and BioSpectrum India both reported that Avaana Capital and Shastra VC co-led the funding. ETtech put the amount at approximately US$4 million; that is a reported approximate conversion, while the announced rupee figure is ₹36.5 crore.
The reports do not state the company’s valuation, the amount of equity or dilution involved, the investment instrument, or a detailed allocation of the proceeds. They also describe NuSynth’s location differently: BioSpectrum and ETtech call it Mysuru-based, while other same-day coverage uses Bengaluru. Without company confirmation, neither should be treated here as a definitive headquarters.
What NuSynth Technologies does
NuSynth is building an R&D-led process-innovation platform for complex chemistry. The company’s stated approach is to redesign processes from first principles by examining the starting materials, reaction pathways and process economics—not simply to optimize a single step in an existing route.
#1 Best Overall
Its announced evaluation objectives include improving cost efficiency, yield, cycle time, safety, sustainability and the ability to scale a process commercially. These are intended outcomes described in funding coverage, not independently verified results or measured improvements. The company’s approach therefore concerns the design of synthesis routes and their economics, rather than a claim that any specific route has already outperformed an established process.
Initial target sectors
The company named pharmaceuticals and electronics chemicals as its initial sectors. The funding reports do not identify customers, commercial deployments or specific processes already in use. They also do not describe a released software product or explain whether customers will access the platform through software, services, licensed processes or another model.
How NuSynth plans to use the funding
The announced priorities are to strengthen R&D and technology capabilities, develop an initial portfolio of proprietary processes, build scale-up capabilities and grow the team. No amounts or percentages are assigned to those areas in the coverage, so the round should not be read as having a published line-by-line spending plan.
Recommended Free Tools
NuSynth co-founder and CEO Poorvank Purohit framed the opportunity as moving beyond manufacturing established chemistry toward innovation in the underlying chemistry itself. Avaana Capital partner Shruti Srivastava similarly described proprietary synthesis pathways that could be more efficient and commercially scalable as important to the next phase of high-performance industrial chemistry in India. Those statements explain the rationale for the investment; they do not establish that NuSynth has already achieved the targeted process advantages.
How to assess the proposed process improvements
NuSynth’s stated goals can be considered across several distinct measures: cost efficiency, yield, cycle time, safety, sustainability and commercial scale-up. These are evaluation objectives, not published head-to-head results against conventional routes. A process might improve one measure without improving all the others, and the announcement coverage gives no figures or examples that would allow a reader to compare current and proposed routes on any of them.
The stated focus on starting materials, reaction pathways and process economics indicates the areas the company intends to revisit. The announcement does not name a specific chemical process, give a baseline for comparison, or report validated performance data. Its next milestones, as described, are capability-building: develop proprietary processes, prepare for scale-up and expand the team.
Rank #4
What the announcement does—and does not—establish
- Established by the reports: a ₹36.5 crore seed round co-led by Avaana Capital and Shastra VC, NuSynth’s focus on process innovation in complex chemistry, and pharmaceuticals and electronics chemicals as initial target sectors.
- Stated plans and goals: building R&D, proprietary-process and scale-up capabilities, expanding the team, and pursuing better efficiency, yield, cycle time, safety and sustainability.
- Not established in the reports: valuation, dilution, investment instrument, a detailed use-of-funds breakdown, customer list, commercial deployments, released software or independently measured process improvements.
The funding announcement is therefore best understood as an early-stage industrial R&D investment: it describes the capabilities NuSynth intends to build, rather than reporting validated operating results. The same-day coverage dated 13 October 2026 from The Economic Times/ETtech, BioSpectrum India and Analytics India Magazine provides the basis for the funding and company details; the reports do not surface an official company announcement.
Frequently Asked Questions
How much funding did NuSynth Technologies raise?
NuSynth raised ₹36.5 crore in seed funding. The Economic Times/ETtech also reported an approximate equivalent of US$4 million.
Who led NuSynth’s seed round?
Avaana Capital and Shastra VC co-led the ₹36.5 crore seed round.
What does NuSynth Technologies do?
NuSynth is developing an R&D-led platform for process innovation in complex chemistry. Its stated approach is to rethink starting materials, reaction pathways and process economics.
Which sectors is NuSynth targeting first?
The company named pharmaceuticals and electronics chemicals as its initial target sectors. Coverage does not identify customers or commercial deployments.
Has NuSynth demonstrated improved yields or lower costs?
The funding coverage describes improvements in cost efficiency, yield, cycle time, safety, sustainability and scale-up as goals. It does not report independently measured results or specific process comparisons.
The Bottom Line
NuSynth’s ₹36.5 crore seed round, co-led by Avaana Capital and Shastra VC, is intended to build its complex-chemistry R&D, proprietary-process and scale-up capabilities. The announced process benefits remain goals, not independently verified results.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
